Yayınlar | Akademik Arşiv

REF #2026-01

Durable CNS remission with elranatamab and intrathecal therapy in relapsed/refractory multiple myeloma

REF #2026-02

Coexistence of Multiple Myeloma and Gaucher Disease: A Pilot Study

REF #2026-03

Choroidal Leakage during Daratumumab Therapy: A Desensitization-Based Strategy for Treatment Continuation in Relapsed/Refractory Multiple Myeloma

REF #2026-04

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

Yazarlar: Cyrille Touzeau, Roberto Mina, Hang Quach, Vania Hungria, Divaya Bhutani, Wenming Chen, Swarup Kumar, Chakra Chaulagain, Meletios Athanasios Dimopoulos, Nizar J. Bahlis, Senem Maral, Niels W.C.J. van de Donk, Jayr Schmidt Filho, Khalid Saja, Raphael Teipel, Miki Ando, Wilfried Roeloffzen, Ombretta Annibali, Bradley Augustson, Cirino Botta, Michel Delforge, Emmanuelle Bourgeois, Gabriele Buda, Marek Hus, Aurore Perrot, Meir Preis, Meral Beksac, Ludek Pour, Sarah Farmer, Marta Nunes, Albert Oriol, Thomas Melchardt, Yu Hu, Max Flogegård, Dai Wang, Lixia Pei, Susan Wroblewski, Ingrid M. Ariës, Natalia A. Quijano Cardé, Tatiana Perova, Tertia de Jager, Tzu-Min Yeh, Veronique Vanquickelberghe, Priya Shah, Katherine Chastain, Rachel Kobos, Robin Carson, and Ola Landgren.

Makaleyi Görüntüle

REF #2026-05

Approaching Cure in Multiple Myeloma: A Dual-Center Experience Among Patients Diagnosed Before 2010

REF #2026-06

The Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous Solid Tumor History

REF #2026-07

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study

REF #2026-08

Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes

REF #2026-09

[11C]-Methionine PET/CT in evaluation of bone marrow infiltration and usage as a prognostic tool in multiple myeloma

REF #2026-10

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)

REF #2026-11

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma

Yazarlar: Roberto Mina, Meral Beksac, Paula Rodríguez-Otero, Wenming Chen, María-Victoria Mateos, Jian Li, Philippe Moreau, Yael C Cohen, Chang-Ki Min, Tomas Jelinek, Jing Christine Ye, Hila Magen, Samuel M Rubinstein, Weijun Fu, Vania Hungria, Guldane Cengiz Seval, Joao Samuel Farias, Jakub Radocha, Senem Maral, Mehmet Turgut, Youngil Koh, Daniel O'Leary, Jayr Schmidt Filho, Raymond Thertulien, Gang An, Shang-Yi Huang, Sebastian Grosicki, Agata Tyczyńska, Rahul Banerjee, Matthew J Pianko, Joaquín Martínez-López, Pawel Steckiewicz, Dai Maruyama, Kentaro Fukushima, Albert Oriol, Jordi Lopez Pardo, Hartmut Goldschmidt, Charlotte Pawlyn, Aurore Perrot, Elena Zamagni, Meletios A Dimopoulos, Leo Rasche, Jaszianne Tolbert, William Terry, Christelle Courtoux, Xiao Liu, Sandra Y Vasey, Kaitlyn Connors, Mariacristina Festa, Christoph Heuck, Angélique Langlois, Lisa O'Rourke, Jiangxiu Zhou, Xiang Qin, Jiashen Lu, Joy Gong, Diego Vieyra, Peter M Voorhees; MonumenTAL-3 Investigators

Makaleyi Görüntüle

REF #2026-12

Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS

Yazarlar: Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Marc Braunstein, Ludek Pour, Josep Marti, Supratik Basu, Yael C Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Wojciech Maciej Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Weiping Liu, Jianping Wang, Emilie Van Brummelen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Fredrik Borgsten, Melissa Rowe, Robin Carson, Saad Z Usmani

Makaleyi Görüntüle

REF #2026-13

Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review

REF #2026-14

Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience

REF #2026-15

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

Yazarlar: Cyrille Touzeau, Roberto Mina, Hang Quach, Vania Hungria, Divaya Bhutani, Wenming Chen, Swarup Kumar, Chakra Chaulagain, Meletios Athanasios Dimopoulos, Nizar J Bahlis, Senem Maral, Niels W C J van de Donk, Jayr Schmidt Filho, Khalid Saja, Raphael Teipel, Miki Ando, Wilfried Roeloffzen, Ombretta Annibali, Bradley Augustson, Cirino Botta, Michel Delforge, Emmanuelle Bourgeois, Gabriele Buda, Marek Hus, Aurore Perrot, Meir Preis, Meral Beksac, Ludek Pour, Sarah Farmer, Marta Nunes, Albert Oriol, Thomas Melchardt, Yu Hu, Max Flogegård, Dai Wang, Lixia Pei, Susan Wroblewski, Ingrid M Ariës, Natalia A Quijano Cardé, Tatiana Perova, Tertia de Jager, Tzu-Min Yeh, Veronique Vanquickelberghe, Priya Shah, Katherine Chastain, Rachel Kobos, Robin Carson, Ola Landgren; MajesTEC-9 Trial Investigators

Makaleyi Görüntüle

REF #2026-16

Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes

REF #2026-17

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis

Yazarlar: Efstathios Kastritis, Giovanni Palladini, Monique C Minnema, Ashutosh D Wechalekar, Arnaud Jaccard, Hans C Lee, Vaishali Sanchorawala, Peter Mollee, Jin Lu, Stefan O Schönland, Moshe E Gatt, Kenshi Suzuki, Kihyun Kim, M Teresa Cibeira, Manisha Bhutani, Meral Beksac, Edward N Libby, Jason Valent, Vania Hungria, Michael A Rosenzweig, Naresh Bumma, Antoine Huart, Meletios-Athanasios A Dimopoulos, Divaya Bhutani, Adam Waxman, Stacey Goodman, Jeffrey A Zonder, Selay Lam, Kevin W Song, Timon Hansen, Salomon Manier, Wilfried W H Roeloffzen, Krzysztof Jamroziak, Fiona Kwok, Chihiro Shimazaki, Jin-Seok Kim, Edvan de Queiroz Crusoé, NamPhuong Tran, Jianping Wang, Yuping Chen, Sandra Y Vasey, Jordan M Schecter, Jessica Vermeulen, Raymond Comenzo, Giampaolo Merlini

Makaleyi Görüntüle

REF #2026-18

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

Yazarlar: Shaji Kumar, Sundar Jagannath, Katja C Weisel, Laura Rosiñol, Xavier Leleu, Meletios-Athanasios Dimopoulos, Efstathios Kastritis, David S Siegel, Jorge Monge, Juan Du, Javier de la Rubia, Pedro Asensi Cantó, Jae Hoon Lee, María-Victoria Mateos, Borja Puertas, Alessandro Gozzetti, Dominik Dytfeld, Enrique M Ocio, Joan Blade, Shuji Ozaki, Meral Beksac, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Nicolle Bonar, Paul Spin, Mostafa Shokoohi, Muhaimen Siddiqui, Di Wang, Kevin Hou, Michael E D West, Christian Hampp, Jeannette Green, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel E Sobel, Jessica J Jalbert, Glenn S Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Brian G M Durie

Makaleyi Görüntüle

REF #2026-19

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study

Yazarlar: Rakesh Popat, Meral Beksac, Meletios A Dimopoulos, Moshe E Gatt, Francesca Gay, Jae-Cheol Jo, Prashant Kapoor, Eirini Katodritou, K Martin Kortüm, Silvia Ling, Chandramouli Nagarajan, Kenshi Suzuki, Lugui Qiu, Maika Onishi, Grace Ku, Monique Dail, Nabanita Mukherjee, Jeremy A Ross, Mohamed Ali Badawi, Mary Jean Fusco, Edyta Dobkowska, Emma Arriola, Orlando F Bueno, Nizar J Bahlis, Shinsuke Iida, Philippe Moreau, Jason Valent, María-Victoria Mateos

Makaleyi Görüntüle

REF #2026-20

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study

REF #2026-21

A comparison of cryopreserved and noncryopreserved peripheral blood hematopoietic stem cells for autologous transplantation in multiple myeloma: a study from the chronic malignancies working party of the EBMT

Yazarlar: Mohammed Amine Bekadja, Luuk Gras, Laurien Baaij, Linda Koster, Nada Hamad, Ben Carpenter, Emma Nicholson, Victoria Potter, Annoek E C Broers, Didier Blaise, Jenny Louise Byrne, Anne Huynh, Francesca Kinsella, Péter Reményi, Matthew P Collin Sr, John G Gribben, Simon Bulley, Alessandra Tucci, Natalia De Las Heras, Joanna Drozd-Sokolowska, Kavita Raj, Meral Beksac, Stefan Schönland, Patrick J Hayden, John Snowden, Mahmoud Deeb Aljurf, Donal P McLornan, Damiano Rondelli, A Sureda, Laurent Garderet, Dietger Niederwieser

Makaleyi Görüntüle

REF #2026-22

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (Dara) ± Pomalidomide (Pom) vs Dara Plus Pom and Dexamethasone (DPD) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

Yazarlar: Peter Voorhees, Roberto Mina, Paula Rodríguez-Otero, Wenming Chen, María-Victoria Mateos, Jian Li, Philippe Moreau, Yael Cohen, Chang-Ki Min, Roman Hájek, Jing Christine Ye, Hila Magen, Sam Rubinstein, Weijun Fu, Vania Hungria, Güldane Cengiz Seval, João De Holanda Farias, Jakub Radocha, Senem Maral, Memet Turgut, Youngil Koh, Daniel O'Leary, Jayr Schmidt, Raymond Thertulien, Gang An, Jeffrey Huang, Sebastian Grosicki, Agata Tyczyńska, Rahul Banerjee, Matthew J. Pianko, Joaquín Martinez-Lopez, Paweł Steckiewicz, Dai Maruyama, Kentaro Fukushima, Albert Oriol, Jordi Lopez Pardo, Hartmut Goldschmidt, Charlotte Pawlyn, Aurore Perrot, Elena Zamagni, Meletios A. Dimopoulos, Leo Rasche, Jaszianne Tolbert, William Terry, Christelle Courtoux, Xiao Liu, Sandra Vasey, Kaitlyn Connors, Mariacristina Festa, Christoph Heuck, Angélique Langlois, Lisa O'Rourke, Jiangxiu Zhou, Xiang Qin, Jiashen Lu, Jue Gong, Diego Vieyra, Meral Beksaç

Abstract Görüntüle

REF #2026-23

Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial

Yazarlar: Sagar Lonial, Meletios A Dimopoulos, Maria Gavriatopoulou, Kihyun Kim, Chang-Ki Min, Albert Oriol, Catarina Campos Costa Moreira, Hang Quach, Lugui Qiu, Zhongjun Xia, Fredrik Schjesvold, Ignacio Casas-Avilés, Yan Xu, Vania Hungria, Güldane C Seval, Baijun Fang, Charalampia Kyriakou, Henry Miles Prince, Junling Zhuang, Hsin-Chen Lin, María-Victoria Mateos, Ivan Špička, Angelo Maiolino, Filiz Vural, Supratik Basu, Dominik Dytfeld, Chengcheng Fu, Phoebe Joy Ho, Nisha Joseph, Michael Low, Ludek Pour, Saulius Girnius, Jesús G Berdeja, Paula Rodríguez Otero, Yiming Cheng, Michael Amatangelo, Sarah Hersey, Christian Kazanecki, Marija Bosilkovska Weisskopf, Margee J Kyada, Patricia C Abad, Shuyu Chu, Juliane Morando, Paulo Maciag, Paul G Richardson, Niels WCJ van de Donk; EXCALIBER-RRMM Investigators

Makaleyi Görüntüle

REF #2026-24

2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group

REF #2025-01

VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Yazarlar: Efstathios Kastritis, Meral Beksac, Sorina Nicoleta Badelita, Eirini Katodritou, Jelena Bila, Emmanouil Spanoudakis, Guldane Cengiz Seval, Zorica Cvetkovic, Olivera Markovic, Selami Koçak Toprak, Dimitra Dalampira, Daniel Coriu, Zoi Bezirgiannidou, Mario Pirsic, Toni Valkovic, Iulia Ursuleac, Aleksandra Sretenovic, Angeliki Sevastoudi, Josip Batinic, Sinziana Barbu, Maria Roussou, Maria Gavriatopoulou, Evangelos Terpos, Meletios A Dimopoulos; Balkan Myeloma Study Group

Makaleyi Görüntüle

REF #2025-02

Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group

REF #2025-03

A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide-dexamethasone with pomalidomide-dexamethasone in people with multiple myeloma

REF #2025-04

Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study

REF #2025-05

Familial Multiple Myeloma: Insights From Epidemiology and Underlying Germline Genetic Predisposition to the Clinic

REF #2025-06

Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel

REF #2025-07

Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network

Yazarlar: Niels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, Maria-Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksac, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte Lbm Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hajek, Heinz Ludwig, Carlos Fernandez de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodriguez-Otero, Kwee Yong, Leo Rasche, Evangelos Terpos, Marc S Raab, Mario Boccadoro, Pieter Sonneveld, Hermann Einsele; EMN Guidelines Committee

Makaleyi Görüntüle

REF #2025-08

Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT

REF #2025-09

Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma

REF #2025-10

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Transplant-ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

REF #2025-11

Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)

Yazarlar: Meletios A. Dimopoulos, Peter Voorhees, Fredrik Schjesvold, Yael C. Cohen, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross I. Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac, Keith Stockerl-Goldstein, Albert Oriol, Gabor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Spicka, Anne K. Mylin, Sara Bringhen, Katarina Uttervall, Bartosz Pula, Eva Medvedova, Andrew J. Cowan, Phillippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar

Makaleyi Görüntüle

REF #2025-12

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia

REF #2025-13

Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial

REF #2025-14

Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial

REF #2025-15

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Yazarlar: Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Philippe Moreau, María-Victoria Mateos, Sonja Zweegman, Gordon Cook, Monika Engelhardt, Michel Delforge, Roman Hajek, Fredrik Schjesvold, Francesca Gay, Salomon Manier, Katja C Weisel, Martin Kaiser, Niels W C J van de Donk, Elena Zamagni, Paula Rodriguez-Otero, Aurore Perrot, Christoph Driessen, Jelena Bila, Edward Laane, Dominik Dytfeld, Cyrille Touzeau, Meral Beksac, Marc S Raab, Michele Cavo, Mohamad Mohty, Andrew Spencer, Heinz Ludwig, Hermann Einsele, Jesus San-Miguel, Pieter Sonneveld

Makaleyi Görüntüle

REF #2025-16

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Yazarlar: Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, Yael C Cohen, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross I Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac, Keith Stockerl-Goldstein, Albert Oriol, Gabor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Spicka, Anne K Mylin, Sara Bringhen, Katarina Uttervall, Bartosz Pula, Eva Medvedova, Andrew J Cowan, Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G Katz, Els Rousseau, Liang Li, Robyn M Dennis, Robin Carson, S Vincent Rajkumar; AQUILA Investigators

Makaleyi Görüntüle

REF #2025-17

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant

Yazarlar: Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Marc Braunstein, Ludek Pour, Josep M Martí, Supratik Basu, Yael C Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Tahamtan Ahmadi, Weiping Liu, Jianping Wang, Katherine Chastain, Jessica Vermeulen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Sonja Zweegman

Makaleyi Görüntüle

REF #2025-18

Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

Yazarlar: Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, Maria-Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksac, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte L B M Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hajek, Jelena Bila, Guldane C Seval, Michael O'Dwyer, Heinz Ludwig, Carlos Fernandez de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodriguez-Otero, Kwee Yong, Marin Kortüm, Leo Rasche, Evangelos Terpos, Marc S Raab, Mario Boccadoro, Pieter Sonneveld, Hermann Einsele; EMN Guidelines Committee

Makaleyi Görüntüle

REF #2025-19

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

REF #2025-20

Somatic variants and frequencies of familial myeloma germline predisposition genes among patients within the CoMMpass dataset

REF #2025-21

Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods

REF #2025-22

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials

Yazarlar: María-Victoria Mateos, Suzanne Trudel, Hang Quach, Paweł Robak, Meral Beksac, Ludek Pour, Marek Hus, Kihyun Kim, Vera Zherebtsova, Sosana Delimpasi, Tomas Jelínek, Christopher Ward, P Joy Ho, Vladimir Vorobyev, Marcelo Pitombeira de Lacerda, Gracia Aparecida-Martinez, Ivan Spicka, Jakub Radocha, Michele Cavo, Claudio Cerchione, Chengcheng Fu, Kazuhito Suzuki, Rachel Rogers, Amy Phillips-Jones, Zhaohui Wang, Hena Baig, Jodie Wilkes, Xiaoou L Zhou, Eric Lewis, Lydia Eccersley, Neal Sule, Prani Paka, Joanna B Opalinska, Pralay Mukhopadhyay, Vania Hungria, Meletios Athanasios Dimopoulos```

Makaleyi Görüntüle

REF #2024-01

CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey

REF #2024-02

Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

REF #2024-03

Original vs. Generic Plerixafor for the Mobilization of Stem Cells in Multiple Myeloma Patients

REF #2024-04

Multipl Miyelomda KAR-T/KAR-NK

REF #2024-05

The Effect of Age on High-Dose Therapy with Autologous Stem Cell Support in Multiple Myeloma: A Single-Center Experience

REF #2024-06

Investigation of cytogenetic abnormalities in newly diagnosed multiple myeloma patients by Optical Genome Mapping (OGM)

REF #2024-07

Somatic variants and frequencies of familial myeloma germline predisposition genes among patients within the CoMMpass dataset

REF #2024-08

A Germline Variant of BNIP1 Gene (rs28199) is Associated with Familial Multiple Myeloma

REF #2024-09

Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases

REF #2024-10

HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma

REF #2024-11

Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study

REF #2024-12

Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases

REF #2024-13

In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

REF #2024-14

Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

REF #2024-15

Transcriptome Analysis of Beta-Catenin-Related Genes in CD34+ Haematopoietic Stem and Progenitor Cells from Patients with AML

REF #2024-16

In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide

REF #2024-17

Lenfoplazmasitik Lenfomada Yeni Nesil Dizileme Yöntemiyle Mutasyon İncelemesinin Tanı ve Tedavi Planında Yeri

REF #2023-01

Addressing Multiple Myeloma in Turkey: A Nationwide Survey by the Turkish Hematology Network Group Highlights Opportunities and Challenges

REF #2023-02

The relationship of bone marrow fibrosis with extramedullary disease in multiple myeloma

REF #2023-03

Efficacy of Daratumumab plus Bortezomib, Cyclophosphamide and Dexamethasone in Patients with Multiple Myeloma Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

REF #2023-04

Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data

REF #2023-05

A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset

REF #2023-06

HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma

REF #2023-07

Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome

REF #2023-08

Upfront autologous transplantation still improving outcomes in patients with multiple myeloma

REF #2023-09

Werner helicase is required for proliferation and DNA damage repair in multiple myeloma

REF #2023-10

Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center

REF #2023-11

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

REF #2022-01

Werner helicase is required for proliferation and DNA damage repair in multiple myeloma

REF #2022-02

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

Yazarlar: Paul G Richardson, Fredrik Schjesvold, Katja Weisel, Philippe Moreau, Larry D Anderson Jr, Darrell White, Paula Rodriguez-Otero, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Meral Beksac, Albert Oriol, Jindriska Lindsay, Anna Marina Liberati, Monica Galli, Pawel Robak, Alessandra Larocca, Munci Yagci, Filiz Vural, Abraham S Kanate, Ruiyun Jiang, Lara Grote, Teresa Peluso, Meletios Dimopoulos

Makaleyi Görüntüle

REF #2022-03

Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?

REF #2022-04

First Experience of 11C-Methionine PET in Multiple Myeloma in Turkey

REF #2022-05

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

REF #2022-06

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

REF #2022-07

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT

REF #2022-08

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Yazarlar: Binod Dhakal, Nina Shah, Ankit Kansagra, Ambuj Kumar, Sagar Lonial, Alfred Garfall, Andrew Cowan, Bishesh Sharma Poudyal, Caitlin Costello, Francesca Gay, Gordon Cook, Hang Quach, Herman Einsele, Jeff Schriber, Jian Hou, Luciano Costa, Mahmoud Aljurf, Maria Chaudhry, Meral Beksac, Miles Prince, Mohamad Mohty, Murali Janakiram, Natalie Callander, Noa Biran, Pankaj Malhotra, Paula Rodriguez Otero, Philippe Moreau, Rafat Abonour, Raheel Iftikhar, Rebecca Silberman, Sham Mailankody, Tara Gregory, Yi Lin, Paul Carpenter, Mehdi Hamadani, Saad Usmani, Shaji Kumar

Makaleyi Görüntüle

REF #2022-09

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

REF #2022-10

Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia

REF #2022-11

Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Yazarlar: Sinem Civriz Bozdağ, Güldane Cengiz Seval, İpek Yönal Hindilerden, Fehmi Hindilerden, Neslihan Andıç, Mustafa Baydar, Lale Aydın Kaynar, Selami Koçak Toprak, Hasan Sami Göksoy, Berrin Balık Aydın, Ufuk Demirci, Ferda Can, Vildan Özkocaman, Eren Gündüz, Zeynep Tuğba Güven, Zübeyde Nur Özkurt, Sinan Demircioğlu, Meral Beksaç, İdris İnce, Umut Yılmaz, Hilal Eroğlu Küçükdiler, Elgün Abishov, Boran Yavuz, Ünal Ataş, Yaşa Gül Mutlu, Volkan Baş, Fahir Özkalemkaş, Hava Üsküdar Teke, Vildan Gürsoy, Serhat Çelik, Rafiye Çiftçiler, Münci Yağcı, Pervin Topçuoğlu, Özcan Çeneli, Hamza Abbasov, Cem Selim, Muhlis Cem Ar, Orhan Kemal Yücel, Sevil Sadri, Canan Albayrak, Ahmet Muzaffer Demir, Nil Güler, Muzaffer Keklik, Hatice Terzi, Ali Doğan, Zeynep Arzu Yegin, Meltem Kurt Yüksel, Soğol Sadri, İrfan Yavaşoğlu, Hüseyin Saffet Beköz, Tekin Aksu, Senem Maral, Veysel Erol, Leylagül Kaynar, Osman İlhan, Ali Zahit Bolaman, Ömür Gökmen Sevindik, Arzu Akyay, Muhit Özcan, Günhan Gürman, Şule Ünal, Yasemin Yavuz, Reyhan Diz Küçükkaya, Güner Hayri Özsan

Makaleyi Görüntüle

REF #2022-12

Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA

REF #2022-13

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

REF #2022-14

Manual Versus Automated Volume Reduction of Cord Blood

REF #2022-15

Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis

REF #2022-16

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

REF #2022-17

Upfront autologous transplantation still improving outcomes in patients with multiple myeloma

REF #2021-01

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Yazarlar: Efstathios Kastritis, Giovanni Palladini, Monique C Minnema, Ashutosh D Wechalekar, Arnaud Jaccard, Hans C Lee, Vaishali Sanchorawala, Simon Gibbs, Peter Mollee, Christopher P Venner, Jin Lu, Stefan Schönland, Moshe E Gatt, Kenshi Suzuki, Kihyun Kim, M Teresa Cibeira, Meral Beksac, Edward Libby, Jason Valent, Vania Hungria, Sandy W Wong, Michael Rosenzweig, Naresh Bumma, Antoine Huart, Meletios A Dimopoulos, Divaya Bhutani, Adam J Waxman, Stacey A Goodman, Jeffrey A Zonder, Selay Lam, Kevin Song, Timon Hansen, Salomon Manier, Wilfried Roeloffzen, Krzysztof Jamroziak, Fiona Kwok, Chihiro Shimazaki, Jin-Seok Kim, Edvan Crusoe, Tahamtan Ahmadi, NamPhuong Tran, Xiang Qin, Sandra Y Vasey, Brenda Tromp, Jordan M Schecter, Brendan M Weiss, Sen H Zhuang, Jessica Vermeulen, Giampaolo Merlini, Raymond L Comenzo

Makaleyi Görüntüle

REF #2021-02

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

REF #2021-03

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Yazarlar: Laura Rosiñol, Meral Beksac, Elena Zamagni, Niels W C J Van de Donk, Kenneth C Anderson, Ashraf Badros, Jo Caers, Michele Cavo, Meletios-Athanasios Dimopoulos, Angela Dispenzieri, Hermann Einsele, Monika Engelhardt, Carlos Fernández de Larrea, Gösta Gahrton, Francesca Gay, Roman Hájek, Vania Hungria, Artur Jurczyszyn, Nicolaus Kröger, Robert A Kyle, Fernando Leal da Costa, Xavier Leleu, Suzanne Lentzsch, Maria V Mateos, Giampaolo Merlini, Mohamad Mohty, Philippe Moreau, Leo Rasche, Donna Reece, Orhan Sezer, Pieter Sonneveld, Saad Z Usmani, Karin Vanderkerken, David H Vesole, Anders Waage, Sonja Zweegman, Paul G Richardson, Joan Bladé

Makaleyi Görüntüle

REF #2021-04

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Yazarlar: Philippe Moreau, Shaji K Kumar, Jesús San Miguel, Faith Davies, Elena Zamagni, Nizar Bahlis, Heinz Ludwig, Joseph Mikhael, Evangelos Terpos, Fredrik Schjesvold, Thomas Martin, Kwee Yong, Brian G M Durie, Thierry Facon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels van de Donk, Sagar Lonial, Michele Cavo, Sigurdur Y Kristinsson, Suzanne Lentzsch, Roman Hajek, Kenneth C Anderson, Cristina João, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafael Fonseca, Annette Vangsted, Katja Weisel, Rachid Baz, Vania Hungria, Jesus G Berdeja, Fernando Leal da Costa, Angelo Maiolino, Anders Waage, David H Vesole, Enrique M Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloisa Riva, Peter Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf-Henrik Mellqvist, Dominik Dytfeld, Jean-Luc Harousseau, Hartmut Goldschmidt, Jacob Laubach, Nikhil C Munshi, Francesca Gay, Meral Beksac, Luciano J Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z Usmani, Sonja Zweegman, Sarah Holstein, Orhan Sezer, Simon Harrison, Hareth Nahi, Gordon Cook, Maria-Victoria Mateos, S Vincent Rajkumar, Meletios A Dimopoulos, Paul G Richardson

Makaleyi Görüntüle

REF #2021-05

HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA

REF #2021-06

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

REF #2021-07

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

Yazarlar: Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, Bronno van der Holt, Sara Aquino, Heinz Ludwig, Sonja Zweegman, Thilo Zander, Elena Zamagni, Ruth Wester, Roman Hajek, Lucia Pantani, Luca Dozza, Francesca Gay, AnneMaria Cafro, Luca De Rosa, Annamaria Morelli, Henrik Gregersen, Nina Gulbrandsen, Petra Cornelisse, Rosella Troia, Stefania Oliva, Vincent van de Velden, KaLung Wu, Paula F Ypma, Gerard Bos, Mark-David Levin, Luca Pour, Christoph Driessen, Annemiek Broijl, Alexandra Croockewit, Monique C Minnema, Anders Waage, Cecilie Hveding, Niels W C J van de Donk, Massimo Offidani, Giuseppe A Palumbo, Andrew Spencer, Mario Boccadoro, Michele Cavo

Makaleyi Görüntüle

REF #2021-08

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Yazarlar: Heinz Ludwig, Mario Boccadoro, Philippe Moreau, Jesus San-Miguel, Michele Cavo, Charlotte Pawlyn, Sonja Zweegman, Thierry Facon, Christoph Driessen, Roman Hajek, Melitios A Dimopoulos, Francesca Gay, Hervé Avet-Loiseau, Evangelos Terpos, Niklas Zojer, Mohamad Mohty, Maria-Victoria Mateos, Hermann Einsele, Michel Delforge, Jo Caers, Katja Weisel, Graham Jackson, Laurent Garderet, Monika Engelhardt, Niels van de Donk, Xavier Leleu, Hartmut Goldschmidt, Meral Beksac, Inger Nijhof, Niels Abildgaard, Sara Bringhen, Pieter Sonneveld

Makaleyi Görüntüle

REF #2021-09

Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)

REF #2021-10

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Yazarlar: Heinz Ludwig, Pieter Sonneveld, Thierry Facon, Jesus San-Miguel, Hervé Avet-Loiseau, Mohamad Mohty, Maria-Victoria Mateos, Philippe Moreau, Michele Cavo, Charlotte Pawlyn, Sonja Zweegman, Monika Engelhardt, Christoph Driessen, Gordon Cook, Melitios A Dimopoulos, Francesca Gay, Hermann Einsele, Michel Delforge, Jo Caers, Katja Weisel, Graham Jackson, Laurent Garderet, Niels van de Donk, Xavier Leleu, Hartmut Goldschmidt, Meral Beksac, Inger Nijhof, Martin Schreder, Niels Abildgaard, Roman Hajek, Niklas Zojer, Efstathios Kastritis, Annemiek Broijl, Fredrik Schjesvold, Mario Boccadoro, Evangelos Terpos

Makaleyi Görüntüle

REF #2021-11

Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group

REF #2021-12

Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

REF #2021-13

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

REF #2021-14

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

REF #2021-15

Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma

REF #2021-16

A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity

REF #2021-17

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Yazarlar: Patrick J Hayden, Dirk-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Nicolaus Kröger, Hermann Einsele, Monique Minnema, Alida Dominietto, Michael Potter, Jacob Passweg, Arancha Bermúdez, Stephanie Nguyen-Quoc, Uwe Platzbecker, Johanna Tischer, Fabio Ciceri, Joan Hendrik Veelken, Per Ljungman, Nicolaas Schaap, Edouard Forcade, Angelo Michele Carella, Virginie Gandemer, William Arcese, Adrian Bloor, Attilio Olivieri, Laure Vincent, Meral Beksac, Stefan Schönland, Ibrahim Yakoub-Agha

Makaleyi Görüntüle

REF #2021-18

Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review

REF #2021-19

Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors

REF #2021-20

Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications

REF #2021-21

A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT

REF #2021-22

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

REF #2021-23

Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT

REF #2021-24

Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type

REF #2021-25

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

REF #2021-26

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

REF #2020-01

CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation

REF #2020-02

Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma

REF #2020-03

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

REF #2020-04

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy...

Yazarlar: Michele Cavo, Francesca Gay, Meral Beksac, Lucia Pantani, Maria Teresa Petrucci, Meletios A Dimopoulos, Luca Dozza, Bronno van der Holt, Sonja Zweegman, Stefania Oliva, Vincent H J van der Velden, Elena Zamagni, Giuseppe A Palumbo, Francesca Patriarca, Vittorio Montefusco, Monica Galli, Vladimir Maisnar, Barbara Gamberi, Markus Hansson, Angelo Belotti, Ludek Pour, Paula Ypma, Mariella Grasso, Alexsandra Croockewit, Stelvio Ballanti, Massimo Offidani, Iolanda D Vincelli, Renato Zambello, Anna Marina Liberati, Niels Frost Andersen, Annemiek Broijl, Rossella Troia, Anna Pascarella, Giulia Benevolo, Mark-David Levin, Gerard Bos, Heinz Ludwig, Sara Aquino, Anna Maria Morelli, Ka Lung Wu, Rinske Boersma, Roman Hajek, Marc Durian, Peter A von dem Borne, Tommaso Caravita di Toritto, Thilo Zander, Christoph Driessen, Giorgina Specchia, Anders Waage, Peter Gimsing, Ulf-Henrik Mellqvist, Marinus van Marwijk Kooy, Monique Minnema, Caroline Mandigers, Anna Maria Cafro, Angelo Palmas, Susanna Carvalho, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld

Makaleyi Görüntüle

REF #2020-05

Daratumumab Monotherapy for Patients With Intermediate-risk or High-risk Smoldering Multiple Myeloma: A Randomized, Open-label, Multicenter, Phase 2 Study (CENTAURUS)

REF #2020-06

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

REF #2019-01

The Role of the Local Bone Marrow Renin-Angiotensin System in Multiple Myeloma

REF #2019-02

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM)

REF #2019-03

Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM)

REF #2019-04

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM)

REF #2019-05

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies...

REF #2019-06

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Yazarlar: Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, Vladimir Maisnar, Philippe Moreau, Chang Ki Min, Agnieszka Pluta, Wee-Joo Chng, Martin Kaiser, Sonja Zweegman, Maria-Victoria Mateos, Andrew Spencer, Shinsuke Iida, Gareth Morgan, Kaveri Suryanarayan, Zhaoyang Teng, Tomas Skacel, Antonio Palumbo, Ajeeta B Dash, Neeraj Gupta, Richard Labotka, S Vincent Rajkumar

Makaleyi Görüntüle

REF #2018-01

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Yazarlar: Mohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, Michele Cavo, Sandra Lejniece, Meral Beksac, Mohamed Amine Bekadja, Wojciech Legiec, Meletios Dimopoulos, Svetlana Stankovic, Maria Soledad Durán, Valerio De Stefano, Alessandro Corso, Yulia Kochkareva, Edward Laane, Christian Berthou, Hans Salwender, Zvenyslava Masliak, Valdas Pečeliūnas, Wolfgang Willenbacher, João Silva, Vernon Louw, Damir Nemet, Zita Borbényi, Uri Abadi, Robert Schou Pedersen, Peter Černelč, Anna Potamianou, Catherine Couturier, Caroline Feys, Florence Thoret-Bauchet, Mario Boccadoro

Makaleyi Görüntüle

REF #2018-02

Daratumumab Plus Bortezomib And Dexamethasone Versus Bortezomib And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of CASTOR

Yazarlar: Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C. Scott, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria-Victoria Mateos

Makaleyi Görüntüle

REF #2017-01

Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

REF #2017-02

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

REF #2017-03

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

REF #2017-04

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up...

REF #2016-01

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

REF #2016-02

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib...

REF #2016-03

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

REF #2016-04

Phase 2 study of tabalumab, a human anti-B-cellactivating factor antibody, with bortezomib and dexamethasone...

REF #2015-01

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma (ELOQUENT-2)

Yazarlar: Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen, Andrew Belch, Donna Reece, Meral Beksac, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Ka Lung Wu, Anil Singhal, Jesus San-Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth C. Anderson, Paul Richardson

Makaleyi Görüntüle

REF #2015-02

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide?

REF #2015-03

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 trial

REF #2014-01

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

REF #2014-02

Panobinostat plus bortezomib and dexamethasone versus placebo... in patients with relapsed or relapsed and refractory multiple myeloma...

Yazarlar: Jesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, Meral Beksac, Meletios Athanasios Dimopoulos, Ashraf Elghandour, Wieslaw Wiktor Jedrzejczak, Andreas Günther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Paolo Corradini, Suporn Chuncharunee, Je-Jung Lee, Robert L Schlossman, Tatiana Shelekhova, Kwee Yong, Daryl Tan, Tontanai Numbenjapon, Jamie D Cavenagh, Jian Hou, Richard LeBlanc, Hareth Nahi, Lugui Qiu, Hans Salwender, Stefano Pulini, Philippe Moreau, Krzysztof Warzocha, Darrell White, Joan Bladé, WenMing Chen, Javier de la Rubia, Peter Gimsing, Sagar Lonial, Jonathan L Kaufman, Enrique M Ocio, Ljupco Veskovski, Sang Kyun Sohn, Ming-Chung Wang, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Claudia Corrado, Bourras-Rezki Bengoudifa, Florence Binlich, Paul G Richardson

Makaleyi Görüntüle

REF #2013-01

Tumor-associated macrophages as a prognostic parameter in multiple myeloma

Yazarlar: Fortunato Morabito, Sara Bringhen, Alessandra Larocca, Pierre Wijermans, Maria Victoria Mateos, Peter Gimsing, Carla Mazzone, Daniela Gottardi, Paola Omedè, Sonja Zweegman, Juan José Lahuerta, Renato Zambello, Pellegrino Musto, Valeria Magarotto, Martijn Schaafsma, Albert Oriol, Gunnar Juliusson, Chiara Cerrato, Lucio Catalano, Massimo Gentile, Ana Isabel Turel, Anna Marina Liberati, Maide Cavalli, Davide Rossi, Roberto Passera, Stefano Rosso, Meral Beksac, Michele Cavo, Anders Waage, Jesus San Miguel, Mario Boccadoro, Pieter Sonneveld, Antonio Palumbo, Massimo Offidani

Makaleyi Görüntüle

REF #2013-02

Bortezomib, Melphalan, Prednisone (VMP) versus Melphalan, Prednisone, Thalidomide (MPT) in elderly newly diagnosed Multiple Myeloma patients

Yazarlar: Fortunato Morabito, Sara Bringhen, Alessandra Larocca, Pierre Wijermans, Maria Victoria Mateos, Peter Gimsing, Carla Mazzone, Daniela Gottardi, Paola Omedè, Sonja Zweegman, Juan José Lahuerta, Renato Zambello, Pellegrino Musto, Valeria Magarotto, Martijn Schaafsma, Albert Oriol, Gunnar Juliusson, Chiara Cerrato, Lucio Catalano, Massimo Gentile, Ana Isabel Turel, Anna Marina Liberati, Maide Cavalli, Davide Rossi, Roberto Passera, Stefano Rosso, Meral Beksac, Michele Cavo, Anders Waage, Jesus San Miguel, Mario Boccadoro, Pieter Sonneveld, Antonio Palumbo, Massimo Offidani

Makaleyi Görüntüle

REF #2013-03

IMWG consensus on risk stratification in multiple myeloma

REF #2013-04

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

Yazarlar: Antonio Palumbo, Anders Waage, Cyrille Hulin, Meral Beksac, Sonja Zweegman, Francesca Gay, Peter Gimsing, Xavier Leleu, Pierre Wijermans, Gülsan Sucak, Sara Pezzatti, Gunnar Juliusson, Brigitte Pégourié, Martijn Schaafsma, Monica Galli, Ingemar Turesson, Brigitte Kolb, Bronno van der Holt, Ileana Baldi, Jürgen Rolke, Giovannino Ciccone, Marc Wetterwald, Henk Lokhorst, Mario Boccadoro, Philippe Rodon, Pieter Sonneveld

Makaleyi Görüntüle

REF #2013-05

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial

Yazarlar: Roelof Willemze, Stefan Suciu, Giovanna Meloni, Boris Labar, Jean-Pierre Marie, Constantijn J M Halkes, Petra Muus, Martin Mistrik, Sergio Amadori, Giorgina Specchia, Francesco Fabbiano, Francesco Nobile, Marco Sborgia, Andrea Camera, Dominik L D Selleslag, Francois Lefrère Sr, Domenico Magro, Simona Sica, Nicola Cantore, Meral Beksac, Zwi Berneman, Xavier Thomas, Lorella Melillo, Jose E Guimaraes, Pietro Leoni, Mario Luppi, Maria E Mitra, Dominique Bron, Georges Fillet, Erik W A Marijt, Adriano Venditti, Anne Hagemeijer, Marco Mancini, Joop Jansen, Daniela Cilloni, Liv Meert, Paola Fazi, Marco Vignetti, Silvia M Trisolini, Franco Mandelli, Theo de Witte

Makaleyi Görüntüle

REF #2013-06

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

REF #2013-07

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

REF #2012-01

IMWG consensus on maintenance therapy in multiple myeloma

Yazarlar: Heinz Ludwig, Brian G M Durie, Philip McCarthy, Antonio Palumbo, Jésus San Miguel, Bart Barlogie, Gareth Morgan, Pieter Sonneveld, Andrew Spencer, Kenneth C Andersen, Thierry Facon, Keith A Stewart, Hermann Einsele, Maria-Victoria Mateos, Pierre Wijermans, Anders Waage, Meral Beksac, Paul G Richardson, Cyrille Hulin, Ruben Niesvizky, Henk Lokhorst, Ola Landgren, P Leif Bergsagel, Robert Orlowski, Axel Hinke, Michele Cavo, Michel Attal

Makaleyi Görüntüle

REF #2012-02

Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Yazarlar: Antonio Palumbo, Roman Hajek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci, John Catalano, Heinz Gisslinger, Wiesław Wiktor-Jędrzejczak, Mamia Zodelava, Katja Weisel, Nicola Cascavilla, Genadi Iosava, Michele Cavo, Janusz Kloczko, Joan Bladé, Meral Beksac, Ivan Spicka, Torben Plesner, Joergen Radke, Christian Langer, Dina Ben Yehuda, Alessandro Corso, Lindsay Herbein, Zhinuan Yu, Jay Mei, Christian Jacques, Meletios A Dimopoulos

Makaleyi Görüntüle

REF #2012-03

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

Yazarlar: Antonio Palumbo, Anders Waage, Cyrille Hulin, Meral Beksac, Sonja Zweegman, Francesca Gay, Peter Gimsing, Xavier Leleu, Pierre Wijermans, Gülsan Sucak, Sara Pezzatti, Gunnar Juliusson, Brigitte Pégourié, Martijn Schaafsma, Monica Galli, Ingemar Turesson, Brigitte Kolb, Bronno van der Holt, Ileana Baldi, Jürgen Rolke, Giovannino Ciccone, Marc Wetterwald, Henk Lokhorst, Mario Boccadoro, Philippe Rodon, Pieter Sonneveld

Makaleyi Görüntüle

REF #2012-04

Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells

REF #2012-05

Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma

REF #2012-06

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?

REF #2012-07

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

REF #2012-08

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients

REF #2012-09

Role of killer immunoglobulin-like receptor and ligand matching in donor selection

REF #2011-01

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

REF #2011-02

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Yazarlar: Antonio Palumbo, Sara Bringhen, Heinz Ludwig, Meletios A Dimopoulos, Joan Bladé, Maria V Mateos, Laura Rosiñol, Mario Boccadoro, Michele Cavo, Henk Lokhorst, Sonja Zweegman, Evangelos Terpos, Faith Davies, Christoph Driessen, Peter Gimsing, Martin Gramatzki, Roman Hàjek, Hans E Johnsen, Fernando Leal Da Costa, Orhan Sezer, Andrew Spencer, Meral Beksac, Gareth Morgan, Hermann Einsele, Jesus F San Miguel, Pieter Sonneveld

Makaleyi Görüntüle

REF #2011-03

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

REF #2011-04

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

REF #2011-05

Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial

REF #2011-06

The shaping of modern human immune systems by multiregional admixture with archaic humans

REF #2011-07

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

REF #2011-08

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up

REF #2011-09

Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma

REF #2011-10

An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells

REF #2011-11

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients

REF #2011-12

Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma

REF #2010-01

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation...

TÜRK MİYELOM ÇALIŞMA GRUBU